Business Context and Reporting Period
This Form 8-K Current Report was filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on June 24, 2020. The filing details the results of the Company's Annual Meeting of Stockholders held on the same date and reports on regulatory compliance and clinical trial updates.
Key Financial Metrics
This filing is a current report regarding corporate governance and operational events. It does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only quantitative data provided relates to stockholder voting and share counts.
Material Changes and Corporate Actions
- Stockholder Voting Results:
- Proposal 1 (Director Election): Stockholders approved the election of Joseph Gardner and Steven Prelack as Class III directors. Significant broker non-votes were recorded (11,630,079 shares).
- Proposal 2 (Reverse Stock Split): Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split of common stock at a ratio of 1-for-15 to 1-for-25, with the specific ratio to be determined by the Board.
- Proposal 3 (Auditor Ratification): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
- Nasdaq Compliance: On June 11, 2020, the Company received notification from Nasdaq that it regained compliance with the $1.00 minimum bid price requirement after maintaining a closing bid price above $1.00 for at least ten consecutive trading days.
- Clinical Trial Update: On June 24, 2020, the Company announced the initiation of a 28-day Phase 2 trial for Razuprotafib in the treatment of glaucoma.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or management commentary regarding future earnings. The primary operational outlook is the commencement of the Phase 2 Razuprotafib glaucoma trial. The successful approval of the reverse stock split indicates a strategic move to maintain listing standards and potentially improve stock liquidity.
Investor Verification Checklist
- Verify the specific reverse stock split ratio (1-for-15 to 1-for-25) once determined by the Board of Directors.
- Review the Definitive Proxy Statement filed on April 27, 2020, for detailed background on the director nominees and the rationale for the reverse split.
- Monitor the progress and preliminary data of the newly initiated Phase 2 Razuprotafib glaucoma trial.
- Confirm the Company's continued compliance with Nasdaq listing requirements following the June 11, 2020 notification.